Medications for Esophageal Cancer
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Esophageal Cancer.
Found 5 Approved Drugs for Esophageal Cancer
Nivolumab
Brand Names
Opdivo, Opdualag, Opdivo QVANTIG
Nivolumab
Brand Names
Opdivo, Opdualag, Opdivo QVANTIG
Form: Injection
Method of administration: Subcutaneous, Intravenous
FDA approval date: December 22, 2014
Classification: Endoglycosidase
OPDIVO QVANTIG is a combination of nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of: Renal Cell Carcinoma (RCC) adult patients with intermediate or poor risk advanced RCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab.
Pembrolizumab
Brand Names
Keytruda QLEX, Keytruda
Pembrolizumab
Brand Names
Keytruda QLEX, Keytruda
Form: Injection
Method of administration: Subcutaneous, Intravenous
FDA approval date: January 15, 2015
Classification: Programmed Death Receptor-1 Blocking Antibody
KEYTRUDA QLEX is a combination of pembrolizumab, a programmed death receptor-1 (PD-1)-blocking antibody, and berahyaluronidase alfa, an endoglycosidase, indicated: Melanoma for the treatment of adult patients with unresectable or metastatic melanoma.
Yervoy
Generic Name
Ipilimumab
Yervoy
Generic Name
Ipilimumab
Form: Injection
Method of administration: Intravenous
FDA approval date: March 25, 2011
Classification: CTLA-4-directed Blocking Antibody
YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab.
Tevimbra
Generic Name
Tislelizumab-jsgr
Tevimbra
Generic Name
Tislelizumab-jsgr
Form: Injection
Method of administration: Intravenous
FDA approval date: March 14, 2024
Classification: Programmed Death Receptor-1 Blocking Antibody
TEVIMBRA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for: Esophageal Cancer as a single agent in adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor.
Showing 1-5 of 5
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances